(CercleFinance.com) – Transgene shares were boosted Monday morning on the Paris Stock Exchange by the presentation of the promising results of a clinical trial devoted to its therapeutic cancer vaccine project.
The biotech company announced this morning that the study showed that TG4001 can induce immune responses in HPV16-positive anogenital cancer in an ongoing phase II trial.
At this stage, 58% of patients who received TG4001 in addition to avelumab (Bavencio) from Merck Serono and Pfizer showed an increase in immune responses against HPV antigens, compared to 9% in the avelumab arm, specifies Transgene.
The company states that at the start of the study, only four out of 46 patients showed a reaction against HPV virus antigens, but that the onset of an immune response was detected after 43 days and tended to s intensify after 85 days.
These results were presented during a poster held at the annual meeting of the American Society of Clinical Oncology (ASCO), which is currently being held in Chicago.
The title jumped about 30% after this announcement, while the CAC Mid & Small index rose only 0.4%.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
